Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
HALO last changed hands at $108.40 (down 1.82%). At $12.30B, Halozyme Therapeutics is ranked #777 by size among the 800 stocks on BeStock.
Over a full year the shares have ranged across $61.23 to $116.85, which puts the current price roughly 85% of the way up that band. Holders are ahead 44.6% over twelve months, and up 40.8% across the last three months.
On the chart it holds above both the 50-day ($101.77) and 200-day ($77.87) moving averages; RSI is 55, and the last 30 sessions moved at roughly 25% annualized volatility.
Buyers are paying 31.8 times trailing earnings.
6 analysts follow the stock and the average call is "buy". The mean target, $103.83, sits 4.2% under where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
6 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
HALO is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $103.83, 4.2% below today’s price, with a consensus rating of Buy.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -1.8% | Bearish |
| Price vs 50-day average | +6.5% | Bullish |
| Price vs 200-day average | +39.2% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 54.9 | Bullish |
| MACD (12,26,9) | 2.89 | Bearish |
| Bollinger band position | 31% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 1, 2026 2:40 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$108.40 is the latest print for HALO, a move of -1.82% against yesterday's close of $110.40. Today's low and high so far: $107.86 and $110.49.
Equity value comes to $12.30B at the current price. By that measure it is number 777 of the 800 names in our coverage.
Buyers pay 31.8 times the last twelve months of profit (EPS $2.56).
The year's floor is $61.23 and the ceiling $116.85. Shares are 7.2% away from that ceiling.
Our data shows no dividend paid by Halozyme Therapeutics over the trailing twelve months.
Of 6 analysts, 83% say buy, 17% hold and 0% sell. Price targets average $103.83, with the most cautious at $93.00 and the most optimistic at $115.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on HALO.